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Abstract: BACKGROUND AIMS: Liver biopsy (LB) is performed if non-invasive work-up of liver
disease is inconclusive. The examination of liver tissue occasionally reveals normal histology. Long-
term follow-up of such patients has not been performed. METHODS: We identified a total 70 subjects
from our LB database with elevated liver tests and normal liver histology after a mean of 90.5 ± 52.3
(range 15-216) months and conducted reassessment of medical history, physical examination, laboratory
testing, ultrasound, transient elastography and LB if indicated. RESULTS: At follow-up examination,
15 (7 females (f)/8 males (m); 21.4%) subjects had normal liver tests and no further evidence of liver
disease. A subset of 37 (29 f/8 m; 52.9%) subjects had persistently elevated liver tests without evidence
indicating progressive liver disease but the cause thereof remained unexplained also at the follow-up
visit. Three (0 f/3 m; 4.3%) subjects had consumed excessive alcohol with indicators of alcoholic liver
disease. Eleven subjects (4 f/7 m; 15.7%) had developed steatosis on ultrasound examination along with
weight gain and/or biochemical features of the metabolic syndrome. In addition, three (2 f/1 m) patients
developed autoimmune hepatitis, one female presented with primary biliary cirrhosis. One male was
diagnosed with cholangiocellular carcinoma 3 months after the initial evaluation. CONCLUSION: The
clinical course of most patients was benign, but in approximately 20% of the subjects a liver disease
developed. Particular attention should be given to autoimmune liver diseases in subjects with positive
autoantibodies. In addition, lifestyle factors such as weight gain and alcohol consumption were associated
with the manifestation of liver diseases.
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Follow-up of subjects with normal liver histology identifies a substantial 
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Abstract:  
Background: Liver biopsy (LB) is performed to determine the etiology of elevated liver 
enzymes (eLE) if non-invasive work-up has remained inconclusive. The pathological 
examination of liver tissue not infrequently reveals normal histology. To date, no systematic 
long term follow-up of such subjects has been performed.  
Methods: We identified a total of 87 subjects from our LB database with eLE and normal 
liver histology. Of these, 70 (84.2%, 39 women, 18-72yrs; 31 men, 18-74yrs) were available 
for a detailed follow-up evaluation after 90.5±52.3 (range 15-216) months including medical 
history, physical examination, extensive laboratory testing, ultrasound, transient elastography 
and LB if indicated. 
Results: At the follow-up examination, 15 (7/8; 21.4%) subjects had normal LE and did not 
have any evidence of liver disease. Thirty-seven (24/6; 52.9%) subjects had persistently eLE 
but the cause remained enigmatic also at the follow-up visit without evidence indicating 
progressive liver disease. Three (0/3; 4.3%) subjects had consumed excessive amounts of 
alcohol with indicators of alcoholic liver disease. Eleven subjects (4/7; 15.7%) subjects had 
developed steatosis on ultrasound examination along with weight gain and biochemical 
features of the metabolic syndrome. Additionally, 2 female subjects developed autoimmune 
hepatitis, one female primary biliary cirrhosis, and one male subject was diagnosed with 
cholangiocellular carcinoma.  
Conclusion: In approximately 1 in 5 subjects, eLE may be related to a liver disease that is 
missed on LB. Particular attention should be paid to the onset of autoimmune diseases in 
women. Additionally, eLE indicative may herald consecutive hepatic steatosis if accompanied 
by weight gain and laboratory components of the metabolic syndrome. Although discharge 
from care is appropriate for most subjects, adopting a routine of follow-up for patients with 
eLE and normal histology appears clinically advisable. 
Introduction: Microscopic examination of a liver biopsy specimen as a means to 
identify causes and mechanisms of liver injury was introduced by Hans Popper in the first half 
of the 20th century and paved the way to modern hepatology.[1] Although improved 
serological testing and non-invasive assessment of fibrosis have significantly decreased the 
clinical need to perform liver biopsies for previous standard indications in recent years, liver 
biopsy is still performed if the etiology of elevated liver enzymes (eLE; i.e. transaminases – 
aspartate aminotransferase, AST and alanine aminotransferase, ALT or cholestasis indicating 
enzymes – alkaline phosphatase, AP and gamma glutamyl-transpeptidase, GGT) cannot be 
determined by non-invasive means.  
Percutaneous liver biopsy is still the gold standard for establishing a diagnosis and the 
staging of liver diseases although its limitations such as sampling error or inter-observer 
variability are well-recognized.[2] On clinical grounds, the most frequent causes expected and 
identified are seronegative autoimmune diseases (autoimmune hepatitis - AIH, primary biliary 
cirrhosis – PBC, primary sclerosing cholangitis - PSC, drug-induced liver injury – DILI, 
nonalcoholic steatohepatitis – NASH, secondary biliary cirrhosis, secondary sclerosing 
cholangitis, alcohol-related liver diseases or amyloidosis.[3] Of note, a small proportion of 
liver biopsies obtained for these diagnostic indications do not reveal any abnormalities of the 
liver tissue and are assessed as normal liver parenchyma by the pathologist. The prevalence of 
normal liver biopsies in case of unexplained elevations of liver enzymes ranged between 
approximately 3.3%,[4] 6.0%[3] and 10%.[5]  
To our knowledge, no systematic investigation of the subjects with normal histology at 
index liver biopsy has been performed to determine the long term clinical outcome of these 
patients. It is the common clinical routine to discharge these patients from medical care with 
the assurance that the liver is to be regarded as healthy and further investigations are not 
required. We therefore aimed to identify and follow-up all patients at two participating centers 
who had received the diagnosis of a “normal liver” after liver biopsy in order to generate data 
of the long term clinical outcome of these patients. 
 
Material and Methods 
Subjects: Between January 1996 and December 2013 approximately 1400 diagnostic 
liver biopsies had been performed at two centers for various indications. We aimed to identify 
subjects who had percutaneous liver biopsies performed due to repeated elevations of liver 
enzymes after exclusion of history of relevant alcohol intake (>20g/day), viral hepatitis, 
autoimmune hepatitis, primary biliary cirrhosis, Wilson disease, alpha-1-antitrypsin 
deficiency, hereditary hemochromatosis (HFE-associated) or known steatogenic medication. 
Ultrasound examination at the time of LB had revealed normal liver echogenity and 
parenchymal structure in all subjects. Additionally, these patients were not allowed to have 
signs of heart or renal insufficiency or suffer from cancer, auto-immune diseases or systemic 
infections. A detailed chart review identified 87 subjects with normal liver histology who met 
the above mentioned criteria. Of these, 6 subjects who met the criteria but in retrospect did 
not have representative liver biopsy specimens were not contacted. A representative index LB 
was defined as length of specimen ≥15mm or 8-10 portal tracts.[6] Thus, 81 were contacted 
and invited for a follow-up visit and 70 of these were re-evaluated as detailed below. 
Right upper quadrant US examination was performed using an ATL HDI 5000 
machine (Phillips Medical Systems, Vienna, Austria). The examinations were carried out by 
one of five physicians with 5–25 years of experience. The liver was considered ‘normal’ if the 
echogenicity was homogenous and similar to or slightly higher than the echogenicity of the 
renal parenchyma with a normal vascular and biliary architecture. The liver was considered 
‘fatty liver’ if areas of significant increased echogenicity in relation to the renal parenchyma 
were found. The severity of sonographic steatosis was not graded. Transient elastography was 
performed using Fibroscan® (Echosens™, Paris, France) according to the company 
instructions.  
Written informed consent was obtained from all study participants and the study was 
approved of by the local ethics committee (Ethikkommission des Landes Salzburg) and was 
conducted in accordance to the ethical standards of the Helsinki Declaration of 1975 (revised 
in 1983). 
Laboratory Evaluation: Examinations were performed at the time of the liver biopsy 
(January 1996 to Dezember 2012) and at the follow-up visit (January 2014 to June 2014). 
Venous blood was drawn following an overnight fast for determination of liver function tests, 
a full blood count, serum iron status including ferritin, transferrin, transferrin saturation and 
serum iron, C-reactive protein, erythrocyte sedimentation rate (ESR), fasting glucose and 
lipids hepatitis B and C serology and PCR, autoantibody screening (ANA, ASMA, LC, LKM, 
AMA), by standardized automated laboratory methods. 
Histologic examination of liver biopsy samples: All liver biopsy specimens were 
routinely fixed in buffered formalin and embedded in paraffin. Sections were stained with 
hematoxylin-eosin, Mallory trichrome stain for morphological evaluation and Perls´ stain was 
used for determination of liver iron load. All liver biopsies were routinely analysed 
independently by two pathologists and judged as normal liver tissue, thus no inflammatory 
infiltrate was present, no steatosis, no fibrosis and negative iron stain were recorded as 
detailed previously. Hepatic iron and copper content were determined by automated mass 
spectroscopy and calculated as µg/g dry weight in 32/65 patients as clinically indicated and 
were also within limits of normal.[7]  
Statistical analysis: Statistical analyses were carried out using SPSS (SPSS 13.0) 
statistics package. Calculations for differences between the various groups were carried out by 
Student’s t-test or by non-parametric Kruskal-Wallis test in case of non-Gaussian distribution 
of parameters. Associations among the parameters in the different groups were calculated 
using Spearman’s rank correlation technique. Changes of various parameters over time in 
respective groups were analyzed using paired t-tests. 
 
Results 
Patients’ baseline characteristics: The patients’ baseline characteristics are 
summarized in Table 1. They were without immunologic, infectious, malignant or metabolic 
diseases and thus generally healthy apart from persistently eLE. The median time to follow-up 
was 90.9±50.4 months (range 13 – 208 months). 
  female male 
No 39 31 
Age (yrs) 46.1±15.1 39.2±12.5 
BMI (kg/m²) 24.2±2.6 24.7±4.0 
AST (IU/L) 44.6±29.8 51.6±28.1 
ALT (IU/L) 69.9±45.2 86.5±56.4 
AP (IU/L) 143.6±100.9 127.4±63.0 
GGT (IU/L) 222.5±130.2 164.0±63.4 
Cholesterol (mg/dL) 226.3±46.1 229.5±48.3 
Triglyceride (mg/dL) 109.1±46.3 119.1±54.10 
Ferritin (ng/mL) 157.3±121.8 139.2±110.4 
Fasting glucose (mg/dL) 87.4±13.2 82.2±11.5 
Thrombocytes (G/L) 243.6±69.2 234.9±62.6 
Table 1: Baseline characteristics of the study cohort. Abbreviations: BMI – body mass 
index; AST – aspartate aminotransferase; ALT – alanine aminotransferase; AP – alkaline 
phosphatase; GGT – gamma glutamyltranspeptidase; 
 
Clinical results at follow-up visit: All patients were assessed by using current 
standard laboratory, clinical and ultrasound equipment, transient elastography (Fibroscan) in 
order to non-invasively assess the presence and stage of potential liver disease.  
At the follow-up examination, 15 (7/8; 21.4%) subjects had normal LE and did not 
have any evidence of liver disease. Thirty-seven (24/6; 52.9%) subjects had persistently eLE 
but the cause remained enigmatic also at the follow-up visit without evidence indicating 
progressive liver disease. Three (0/3; 4.3%) subjects had consumed excessive amounts of 
alcohol with indicators of alcoholic liver disease. Eleven subjects (4/7; 15.7%) subjects had 
developed steatosis on ultrasound examination along with weight gain and biochemical 
features of the metabolic syndrome. Clinical and biochemical changes in these subjects 
comprised an increase in BMI, serum triglycerides, ALT, GGT, and ferritin along with a 
decrease in serum HDL concentrations. These changes were significantly different from those 
observed in subjects who were had normalized or were unchanged with regard to liver disease 
biochemically and clinically. These changes are reported in detail in Table 2. Additionally, 2 
female subjects developed autoimmune hepatitis, one female primary biliary cirrhosis, and 
one male subject was diagnosed with cholangiocellular carcinoma. One male subject with 
normal LE and elastography had acquired detectable anti-HBc and anti-HBs with 
undetectable HBs-Ag and HBV-DNA consistent with HBV infection and spontaneous 
seroconversion during the follow-up period. As this patient had normal LE and normal 
elastography he was allocated to the appropriate group for calculations.  
Transient elastography: Liver elastography measurement using Fibroscan yielded a 
liver elasticity of 4.5±0.7 kPa in normalized subjects, 4.3±0.6 kPa in unchanged subjects and 
6.0±2.3 kPa in NAFLD subjects. Thus, elasticity was significantly increased in NAFLD 
subjects compared to the other two groups (P<0.001; ANOVA). It was 14.8 kPa (PBC) and 
4.1kPa (AIH) in subjects who were diagnosed with autoimmune disease. Among subjects 
with alcoholic liver disease, 7.1 kPa and 4.7 kPa were measured. Fibroscan results could not 
be obtained from 2 subjects, one with PBC and one with alcoholic liver disease and BMI 36.1 
kg/m². 
  normalized unchanged NAFLD P (ANOVA) 
  15 37 11   
BMI BL 24.0±2.9 24.1±3.4 26.1±3.3   
BMI FU 23.7±2.5 24.8±3.4 29.0±4.5   
dBMI  -0.32±1.16 0.66±1.50 2.83±2.25 <0.001 
          
ALT BL 56.7±54.1 66.2±27.5 98.8±51.8   
ALT FU 23.2±9.2 55.2±32.0 85.0±53.2   
dALT  -33.5±50.4 10.9±27.9 13.7±46 <0.001 
          
AST BL 33.7±24.1 44.1±19.5 65.5±37.8   
AST FU 24.4±6.8 39.9±18.7 60.8±16.7   
dAST   -9.3±13.5  -4.6±0.9  -4.6±21.1 0.427 
          
GGT BL 133.0±134.7 183.3±102.8 233.4±136.7   
GGT FU 51.3±38.1 209.7±108.7 279.5±109.8   
dGGT  -81.5±107.1 26.4±95.2 46.1±155.2 <0.001 
          
TG BL 88.3±37.5 119.4±50.0 140.9±59.3   
TG FU 99.7±42.3 126.9±59.9 169.4±68.4   
dTG 11.4±4.4 7.5±16.0 28.5±9.1 0.027 
          
HDL BL 65.1±15.8 67.2±18.7 67.5±18.4   
HDL FU 66.6±20.0 66.1±19.6 59.1±14.8   
dHDL 1.5±4.2   -1.1±1.0  -8.4±3.6 <0.001 
          
Ferritin BL 153.5±110.0 151.8±104.2 153.8±127.2   
Ferritin FU 109.2±45.5 152.2±133.2 183.0±150.2   
dFerritin  -44.3±14.2 0.36±28.9 29.2±22.9 <0.001 
Table 2: Antropomorphic and biochemical differences between subjects that had normal 
liver, unchanged elevation of liver enzymes and those who developed nonalcoholic fatty 
liver. Abbreviations: BL – baseline; FU – follow-up; BMI – body mass index; AST – 
aspartate aminotransferase; ALT – alanine aminotransferase; AP – alkaline phosphatase; 
GGT – gamma glutamyltranspeptidase; 
 
Baseline predictors of the subsequent clinical course: In order to identify clinical or 
biochemical parameters predictive of the further clinical development multivariate regression 
analysis was performed after adjustment for sex and time to follow-up visit. Patients were 
grouped as 0 – normalized, 1 – unchanged, 2 – NAFLD at follow-up visit. Parameters with 
significant associations in the univariate analysis entered the multivariate model. Thus, 
associations with BMI, ALT, GGT and triglyceride serum concentrations remained intact in 
the multivariate model. Of these, baseline higher ALT and AST values were predictive of 
new-onset NAFLD. Lower serum triglyceride and total cholesterol concentrations were 
independently associated with normalization of transaminases at follow-up. 
 Discussion: Liver biopsy is still the – although imperfect – gold standard for the 
assessment of liver diseases. It allows for grading and staging of a disease and frequently 
elucidates the underlying etiology when extensive laboratory tests retrieve indefinite results. 
Although normal liver histology is not infrequently obtained in subjects who undergo biopsy 
for elevated liver enzymes of unknown origin, to our knowledge the long term outcome of 
such patients has not yet been assessed. As these patients are commonly discharged from 
further hepatology specialist care with the assurance of absence of a relevant liver disease, we 
aimed to systematically assess the clinical outcome of these patients. Our data demonstrate 
that despite normal liver histology at the time of the indicated index biopsy, important entities 
such as autoimmune diseases (AIH, PBC), cancer (undiagnosed cholangiocellular carcinoma) 
and most frequently non-alcoholic fatty liver disease became clinically evident in 
approximately one fifth of the subjects. Clinical judgement suggests that eLE in these subjects 
were likely related to these entities already at baseline. As the rate of normal liver biopsies in 
our study is comparable to rates reported from other studies, our results may be applicable to 
the general clinical setting in Western countries. 
Approximately 80% of all study subjects either had normal LE and no clinical 
evidence of disease or still had eLE but also no evidence of progressive underlying liver 
disease. Hence, the largest proportion of patients with normal LB did not display clinically 
relevant evidence of liver disease several years after the initial biopsy. However, several 
distinct longitudinal clinically relevant courses can be derived from the observations of our 
study population. And treating clinicians should be aware in the daily routine that these may 
affect approximately 20% of subjects.  
These distinct courses are as follows: 1) Autoimmune liver diseases in women: Two 
women who were biopsied due to mildly elevated transaminases and low-titer autoantibodies 
were finally diagnosed with AIH 12 and 26 months after the index biopsy. One of these then 
was already at a progressed stage of AIH. Similarly, one woman who had undergone biopsy 
for unexplained elevation of AP and GGT and negative AMA received the diagnosis of PBC 
at the time of recall. We therefore suggest that particularly in female subjects with a suspicion 
of autoimmune liver disease, a normal biopsy may not definitely exclude these diseases. They 
should likely be followed despite a normal liver biopsy at an earlier time point as the full 
clinical and biochemical picture of these diseases may follow the elevation of liver enzymes. 
2) NAFLD in association with further weight gain: NAFLD has become the most 
frequent liver in recent decades due to the epidemic rise in obesity and it is not surprising that 
subjects receiving the diagnosis NAFLD were the largest group among those with definite 
diagnosis at follow-up. We consider some observations with regard to the disease spectrum of 
NAFLD worth mentioning and clinically relevant. In retrospect, 11 of 11 patients had 
laboratory and clinical signs suggestive of NAFLD already at the time of the index biopsy. 
However, liver tissue revealed no steatosis or other features potentially linked to NAFLD 
such as ballooning, inflammation, fibrosis or iron deposition. At follow-up, they had gained 
further weight and developed unequivocal steatosis on US examination and other 
characteristics of the metabolic syndrome. In these cases, NAFLD was clinically diagnosed. 
On the other hand, 5 patients whose clinical constellation would likewise have suggested 
NAFLD effectively changed lifestyle and lost weight compared to the time of the biopsy. In 
these subjects, normal US, elastography and liver enzymes were observed at follow-up. 
Taking these 2 groups together, we suggest that weight and lifestyle factors were likely 
responsible for the elevation of liver enzymes at baseline, even in the histological absence of 
steatosis. One is tempted to speculate that these subjects represent a novel segment in the 
disease spectrum of NAFLD. In NAFLD, a large proportion of patients with significant 
steatosis and even NASH present with normal transaminases. Our observations indicate that 
on the other end of the spectrum, eLE together with risk indicators suggestive of NAFLD may 
be clinically apparent prior to hepatocellular steatosis. In this group, effective lifestyle 
modifications and weight loss was associated with the normalization of previously eLE. 
Conversely, further weight gain in the absence of effective lifestyle modification may 
aggravate the clinical picture with hepatic steatosis to become apparent subsequently. In 
NAFLD pathogenesis, the two-hit hypothesis with steatosis as the necessary first hit,[8] has 
been replaced by the multiple-parallel-hit hypothesis.[9] One of the implications of the 
multiple-parallel-hit hypothesis is the fact that NAFLD may in fact comprise several similar 
yet distinct clinical manifestations as has also been suggested by analysis of fibrosis patterns 
in NAFLD.[10] Our observations strongly support the multiple-parallel-hit hypothesis, as 
elevation of liver enzymes indicating NAFLD were present even in the absence of 
hepatocellular steatosis. 
In addition to these three large groups, one young male who received a liver biopsy 
due to unexplained elevation of AP and GGT was diagnosed with metastatic cholangiocellular 
carcinoma only three months later and died few weeks after the diagnosis. No evidence 
thereof had been obtained from CT, MRI, MRCP and ERCP immediately prior to the biopsy. 
Even in retrospective analysis of imaging modalities there was no diagnostic hint that would 
have changed the clinical course.  
A change of drinking habits with significantly higher alcohol intake compared to the 
time of biopsy was estimated to be the cause for deterioration in liver enzymes and 
development of steatosis in 3 subjects (1 female, 2 male). Furthermore, one male subject had 
acquired and cleared contact with hepatitis B virus accounting for one hepatitis B infection in 
the whole cohort representing approximately 522 patient years. 
It appears noteworthy, that in this relatively large cohort we were not able to identify a 
single individual with progressive liver disease in whom the cause had remained enigmatic. 
This finding may represent an important aspect to the entity of cryptogenic liver disease since 
these data suggest that truly cryptogenic liver disease may be a very rare diagnosis at least if a 
normal biopsy has been obtained. It has been well documented that genetic modifiers impact 
on liver enzymes. (Chambers wass, Natgen 2012, und yuan waterworth Hum mol gen 2008) 
Even at follow-up, subjects with eLE and no clinical evidence of liver disease comprised the 
largest group in our analysis. One may assume that underlying genetic variations contribute to 
the elevation of LE particularly in this group, since potential explanations for normalization or 
deterioration could be identified in the remaining subjects. 
In summary, our observations suggest that a normal liver biopsy performed for 
diagnostic purposes in case of unexplained elevation of liver enzymes does not definitely 
exclude an underlying yet only subsequently manifesting liver diseases. In particular, 
attention should be paid to the onset of autoimmune diseases in women. Additionally, eLE 
indicative of NAFLD may herald consecutive steatosis and weight gain. These data suggest 
that elevation of transaminases without histological steatosis linked to metabolic risk factors 
may herald the future onset of NAFLD or even represent a unique entity in the spectrum of 
NAFLD. Although discharge from care is clinically appropriate for most subjects, adopting a 
routine of follow-up for patients with eLE and normal histology appears advisable.  
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